451 related articles for article (PubMed ID: 21146713)
21. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2005 Aug; 43(8):3807-10. PubMed ID: 16081915
[TBL] [Abstract][Full Text] [Related]
22. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
23. Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.
Espinel-Ingroff A; Arendrup M; Cantón E; Cordoba S; Dannaoui E; García-Rodríguez J; Gonzalez GM; Govender NP; Martin-Mazuelos E; Lackner M; Lass-Flörl C; Linares Sicilia MJ; Rodriguez-Iglesias MA; Pelaez T; Shields RK; Garcia-Effron G; Guinea J; Sanguinetti M; Turnidge J
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799206
[TBL] [Abstract][Full Text] [Related]
24. Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013).
Castanheira M; Messer SA; Rhomberg PR; Pfaller MA
Diagn Microbiol Infect Dis; 2016 Jun; 85(2):200-4. PubMed ID: 27061369
[TBL] [Abstract][Full Text] [Related]
25. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.
Beyda ND; Lewis RE; Garey KW
Ann Pharmacother; 2012; 46(7-8):1086-96. PubMed ID: 22811350
[TBL] [Abstract][Full Text] [Related]
26. Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida spp. isolates.
Espinel-Ingroff A; Cantón E; Pelaez T; Pemán J
Diagn Microbiol Infect Dis; 2011 May; 70(1):54-9. PubMed ID: 21513843
[TBL] [Abstract][Full Text] [Related]
27. Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
Diagn Microbiol Infect Dis; 2004 Oct; 50(2):113-7. PubMed ID: 15474320
[TBL] [Abstract][Full Text] [Related]
28. Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
Kritikos A; Neofytos D; Khanna N; Schreiber PW; Boggian K; Bille J; Schrenzel J; Mühlethaler K; Zbinden R; Bruderer T; Goldenberger D; Pfyffer G; Conen A; Van Delden C; Zimmerli S; Sanglard D; Bachmann D; Marchetti O; Lamoth F;
Clin Microbiol Infect; 2018 Nov; 24(11):1214.e1-1214.e4. PubMed ID: 29909005
[TBL] [Abstract][Full Text] [Related]
29. Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-d-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus.
Satish S; Jiménez-Ortigosa C; Zhao Y; Lee MH; Dolgov E; Krüger T; Park S; Denning DW; Kniemeyer O; Brakhage AA; Perlin DS
mBio; 2019 Jun; 10(3):. PubMed ID: 31164462
[No Abstract] [Full Text] [Related]
30. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
Carvalhaes CG; Klauer AL; Rhomberg PR; Pfaller MA; Castanheira M
J Clin Microbiol; 2022 Apr; 60(4):e0244921. PubMed ID: 35249367
[TBL] [Abstract][Full Text] [Related]
32. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.
Pfaller MA; Messer SA; Boyken L; Hollis RJ; Rice C; Tendolkar S; Diekema DJ
Diagn Microbiol Infect Dis; 2004 Mar; 48(3):201-5. PubMed ID: 15023430
[TBL] [Abstract][Full Text] [Related]
33.
Pfaller MA; Huband MD; Flamm RK; Bien PA; Castanheira M
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182527
[TBL] [Abstract][Full Text] [Related]
34. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
[TBL] [Abstract][Full Text] [Related]
35. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.
Krishnan-Natesan S; Wu W; Chandrasekar PH
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):135-7. PubMed ID: 22608136
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of disk diffusion method compared to broth microdilution for antifungal susceptibility testing of 3 echinocandins against Aspergillus spp.
Martos AI; Martín-Mazuelos E; Romero A; Serrano C; González T; Almeida C; Puche B; Cantón E; Pemán J; Espinel-Ingroff A
Diagn Microbiol Infect Dis; 2012 May; 73(1):53-6. PubMed ID: 22480568
[TBL] [Abstract][Full Text] [Related]
37. Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii.
Saribas Z; Yurdakul P; Cetin-Hazirolan G; Arikan-Akdagli S
Mycoses; 2012 Mar; 55(2):156-60. PubMed ID: 21668525
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
[TBL] [Abstract][Full Text] [Related]
39. Antifungal susceptibility testing of micafungin against Candida glabrata isolates.
Oliveira ER; Fothergill A; Kirkpatrick WR; Patterson TF; Redding SW
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Apr; 105(4):457-9. PubMed ID: 18329581
[TBL] [Abstract][Full Text] [Related]
40. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.
Arendrup MC; Cuenca-Estrella M; Lass-Flörl C; Hope WW
Drug Resist Updat; 2013 Dec; 16(6):81-95. PubMed ID: 24618110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
